10 Best Pharma Stocks to Buy for Long Term Growth

8. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Number of Hedge Fund Holders: 27 

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a specialty company focused on developing and selling medications for central nervous system (CNS) diseases, including epilepsy, migraine, ADHD, and Parkinson’s disease.  With well-known medications like Qelbree for ADHD, Trokendi XR and Oxtellar XR for epilepsy, as well as treatments for Parkinson’s disease, including Apokyn and Gocovri, the firm has established a significant position in the CNS market.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) achieved impressive financial results for the third quarter of 2024. The company’s overall revenues increased by 14% to $175.7 million. Due to the success of important goods like Qelbree and Gocovri, net product sales increased to $170.3 million. In contrast to a loss during the same time the previous year, operating earnings increased to $40.9 million, and net earnings rose dramatically to $38.5 million, or $0.69 per diluted share.

In Q3 2024, the company’s sales of the non-stimulant ADHD medication Qelbree increased by 68% to $62.4 million. To position itself for future growth in the CNS market, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is also adding promising therapeutic candidates to its pipeline, such as SPN-830, SPN-817, and SPN-820.